NF-кB inhibition by DHMEQ: in vitro antiproliferative effects on pilocytic astrocytoma and concise review of the current literature

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Child's Nervous System

• Publication date

  2020-05-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00381-020-04625-3PMID 32385563
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Multifaceted Role of Annexin A1 in Viral Infections

  2023cited by this paper
• Novel Surgical and Radiologic Risk Factors for Progression or Recurrence of Pediatric Pilocytic Astrocytoma

  2019influential reference
• The benefit of surveillance imaging for paediatric cerebellar pilocytic astrocytoma

  2019cited by this paper
• Amentoflavone Effectively Blocked the Tumor Progression of Glioblastoma via Suppression of ERK/NF- κ B Signaling Pathway.

  2019cited by this paper
• Characteristics, survival and incidence rates and trends of pilocytic astrocytoma in children in the United States; SEER-based analysis.

  2019cited by this paper
• Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.

  2018cited by this paper
• Communication intervention for individuals with Down syndrome: Systematic review and meta-analysis

  2018cited by this paper
• Antineoplastic Effects of NF-κB Inhibition by DHMEQ (Dehydroxymethylepoxyquinomicin) Alone and in Co-treatment with Radio-and Chemotherapy in Medulloblastoma Cell Lines.

  2018cited by this paper
• CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.

  2018cited by this paper
• “Integrated diagnosis” of pilocytic astrocytoma: Molecular diagnostic procedure for an unusual case

  2018cited by this paper
• Targeting CD133 improves chemotherapeutic efficacy of recurrent pediatric pilocytic astrocytoma following prolonged chemotherapy

  2017cited by this paper
• Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia

  2017cited by this paper
• Confidence and self-attribution bias in an artificial stock market

  2017cited by this paper
• PRC1 contributes to tumorigenesis of lung adenocarcinoma in association with the Wnt/β-catenin signaling pathway

  2017cited by this paper
• NF-kappaB Is Involved in the Regulation of EMT Genes in Breast Cancer Cells

  2017cited by this paper
• Cerebellar pilocytic astrocytoma in childhood: Investigating the long-term impact of surgery on cognitive performance and functional outcome

  2017cited by this paper
• NF-κB inhibition is associated with OPN/MMP-9 downregulation in cutaneous melanoma

  2017cited by this paper
• NF-κB Signalling in Glioblastoma

  2017cited by this paper
• The Role of NF-kB Inhibitors in Cell Response to Radiation.

  2016cited by this paper
• Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy.

  2016cited by this paper
• Transcriptional profiles of pilocytic astrocytoma are related to their three different locations, but not to radiological tumor features

  2015cited by this paper
• The association of alcohol consumption with mammographic density in a multiethnic urban population

  2015cited by this paper
• Pilocytic astrocytoma: pathology, molecular mechanisms and markers

  2015influential reference
• NF-κB inhibitor reverses temozolomide resistance in human glioma TR/U251 cells.

  2015cited by this paper
• Molecular analysis of pediatric brain tumors identifies microRNAs in pilocytic astrocytomas that target the MAPK and NF-κB pathways

  2015cited by this paper
• A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study†.

  2015cited by this paper
• Poly (ADP-ribose) polymerase inhibition synergizes with the NF-κB inhibitor DHMEQ to kill hepatocellular carcinoma cells.

  2014cited by this paper
• The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.

  2014cited by this paper
• Pilocytic astrocytoma: a review of genetic and molecular factors, diagnostic and prognostic markers.

  2014cited by this paper
• Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor

  2014influential reference
• Anoikis Induction and Inhibition of Peritoneal Metastasis of Pancreatic Cancer Cells by a Nuclear Factor-κB inhibitor, (-)-DHMEQ [an abstract of dissertation and a summary of dissertation review]

  2014cited by this paper
• Anoikis induction and inhibition of peritoneal metastasis of pancreatic cancer cells by a nuclear factor-κB inhibitor, (-)-DHMEQ.

  2014cited by this paper
• Comparative expression analysis reveals lineage relationships between human and murine gliomas and a dominance of glial signatures during tumor propagation in vitro.

  2013cited by this paper
• Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

  2013cited by this paper
• Inhibition of NF-κB by Dehydroxymethylepoxyquinomicin Suppresses Invasion and Synergistically Potentiates Temozolomide and γ-Radiation Cytotoxicity in Glioblastoma Cells

  2013cited by this paper
• Elevated serine protease HtrA1 inhibits cell proliferation, reduces invasion, and induces apoptosis in esophageal squamous cell carcinoma by blocking the nuclear factor-κB signaling pathway

  2013cited by this paper
• Lomustine Analogous Drug Structures for Intervention of Brain and Spinal Cord Tumors: The Benefit of In Silico Substructure Search and Analysis

  2013cited by this paper
• Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas

  2013cited by this paper
• Pathological and molecular advances in pediatric low-grade astrocytoma.

  2013cited by this paper
• Characterization of Distinct Immunophenotypes across Pediatric Brain Tumor Types

  2013cited by this paper
• Embelin induces apoptosis in human glioma cells through inactivating NF-κB.

  2013cited by this paper
• The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism.

  2012cited by this paper
• Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma.

  2012cited by this paper
• CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

  2012cited by this paper
• Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer

  2012cited by this paper
• Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer

  2012cited by this paper
• Resveratrol reduces TNF-α-induced U373MG human glioma cell invasion through regulating NF-κB activation and uPA/uPAR expression.

  2011cited by this paper
• Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity

  2011cited by this paper
• PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma

  2011cited by this paper
• MAPK pathway activation and the origins of pediatric low‐grade astrocytomas

  2009cited by this paper
• Astrocytes: biology and pathology

  2009cited by this paper
• Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas

  2009cited by this paper
• Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas

  2009cited by this paper
• BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.

  2008cited by this paper
• NF-kappaB controls growth of glioblastomas/astrocytomas.

  2008cited by this paper
• Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.

  2008cited by this paper
• Pediatric glioblastoma cell line shows different patterns of expression of transmembrane ABC transporters after in vitro exposure to vinblastine

  2008cited by this paper
• Frequent recurrence and progression in pilocytic astrocytoma in adults

  2007cited by this paper
• In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro

  2007cited by this paper
• Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP‐1 and NFκB transcription factors

  2007cited by this paper
• Metastasis: recent discoveries and novel treatment strategies.

  2007cited by this paper
• Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.

  2007cited by this paper
• NF-κB controls growth of glioblastomas/astrocytomas

  2007cited by this paper
• Temozolomide in children with progressive low-grade glioma.

  2007cited by this paper
• Aberrant constitutive activation of nuclear factor κB in glioblastoma multiforme drives invasive phenotype

  2007cited by this paper
• Clonogenic assay of cells in vitro

  2006cited by this paper
• Effects of a novel NF‐κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines

  2006cited by this paper
• DHMEQ, a new NF-κB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells

  2006cited by this paper
• A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.

  2005cited by this paper
• A novel NF‐κB inhibitor DHMEQ selectively targets constitutive NF‐κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo

  2005cited by this paper
• O6-Methylguanine-DNA Methyltransferase, O6-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell Lines

  2005cited by this paper
• Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-κB inhibitor

  2004cited by this paper
• Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors.

  2004cited by this paper
• Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

  2004cited by this paper
• A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma.

  2003cited by this paper
• 2-Methoxyestradiol interferes with NF kappa B transcriptional activity in primitive neuroectodermal brain tumors: implications for management.

  2003cited by this paper
• Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma.

  2002cited by this paper
• Pancreatic cancer: Advances in molecular pathology, diagnosis & clinical management, Fazlul H. Sarkar, Michael C. Dugan (Eds.). BioTechniques Books, Eaton Publishing, Natick, MA (1998), 192 pages, $81.95

  2000cited by this paper
• Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C.

  2000cited by this paper
• Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C

  2000cited by this paper
• Oxidative Stress Inhibits Apoptosis in Human Lymphoma Cells*

  1999cited by this paper
• Cerebellar astrocytoma: experience with 54 cases surgically treated at the Mayo Clinic, Rochester, Minnesota, from 1978 to 1990.

  1997cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• Book reviews

  1933cited by this paper

• Unraveling astrocyte behavior in the space brain: Radiation response of primary astrocytes

  2023cites this paper
• Downregulation of TREM2/NF-кB signaling may damage the blood-brain barrier and aggravate neuronal apoptosis in experimental rats with surgically injured brain.

  2022cites this paper
• The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

  2021cites this paper